AB466-1mg / 詢價
- 關(guān)聯(lián)產(chǎn)品
- 客服電話
- 技術(shù)支持
Anti-IgE Antibody (Omalizumab Biosimilar)
Human/Cynomolgus
IgE
Human IgG1-Kappa
Unconjugated
protein A
0.2 μM filtered
PBS, 10% glycerol (pH 7.4)
Less than 1 EU per μg by the LAL method.
（Recommended Dilution Buffer）
PBS (pH 7.4), contains no stabilizers or preservatives.
<p style="line-height: 25px;">> 95% as determined by Bis-Tris PAGE<br />> 95% as determined by HPLC</p>
<p style="line-height: 25px;">Valid for 12 months from date of receipt when stored at -80°C.<br />Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.</p>
ELISA
Immunoglobulin E (IgE) is well known for its role in allergic disease, the manifestations of which are mediated through its two Fc receptors, FcεRI and CD23 (FcεRII). IgE and its interactions with these receptors are therefore potential targets for therapeutic intervention, and exciting progress has been made in this direction. Furthermore, recent structural studies of IgE-Fc, the two receptors, and of their complexes, have revealed a remarkable degree of plasticity at the IgE-CD23 interface and an even more remarkable degree of dynamic flexibility within the IgE molecule.
(1) Sutton BJ, Davies AM. Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. Immunol Rev. 2015 Nov;268(1):222-35. doi: 10.1111/imr.12340. PMID: 26497523.
.png)